Advances in the Development of Enterohemorrhagic Escherichia Coli Vaccines Using Murine Models of Infection
Overview
Affiliations
Enterohemorrhagic Escherichia coli (EHEC) strains are food borne pathogens with importance in public health. EHEC colonizes the large intestine and causes diarrhea, hemorrhagic colitis and in some cases, life-threatening hemolytic-uremic syndrome (HUS) due to the production of Shiga toxins (Stx). The lack of effective clinical treatment, sequelae after infection and mortality rate in humans supports the urgent need of prophylactic approaches, such as development of vaccines. Shedding from cattle, the main EHEC reservoir and considered the principal food contamination source, has prompted the development of licensed vaccines that reduce EHEC colonization in ruminants. Although murine models do not fully recapitulate human infection, they are commonly used to evaluate EHEC vaccines and the immune/protective responses elicited in the host. Mice susceptibility differs depending of the EHEC inoculums; displaying different mortality rates and Stx-mediated renal damage. Therefore, several experimental protocols have being pursued in this model to develop EHEC-specific vaccines. Recent candidate vaccines evaluated include those composed of virulence factors alone or as fused-subunits, DNA-based, attenuated bacteria and bacterial ghosts. In this review, we summarize progress in the design and testing of EHEC vaccines and the use of different strategies for the evaluation of novel EHEC vaccines in the murine model.
P22-Based Nanovaccines against Enterohemorrhagic Escherichia coli.
Huerta-Saquero A, Chapartegui-Gonzalez I, Bowser S, Khakhum N, Stockton J, Torres A Microbiol Spectr. 2023; :e0473422.
PMID: 36943089 PMC: 10100862. DOI: 10.1128/spectrum.04734-22.
The Diversity of Pathotypes and Vaccination Strategies against This Versatile Bacterial Pathogen.
Pokharel P, Dhakal S, Dozois C Microorganisms. 2023; 11(2).
PMID: 36838308 PMC: 9965155. DOI: 10.3390/microorganisms11020344.
GlnH, a Novel Antigen That Offers Partial Protection against Verocytotoxigenic Infection.
Quinn C, Tomas-Cortazar J, Ofioritse O, Cosgrave J, Purcell C, McAloon C Vaccines (Basel). 2023; 11(1).
PMID: 36680019 PMC: 9863631. DOI: 10.3390/vaccines11010175.
Genomics and pathotypes of the many faces of Escherichia coli.
Geurtsen J, de Been M, Weerdenburg E, Zomer A, McNally A, Poolman J FEMS Microbiol Rev. 2022; 46(6).
PMID: 35749579 PMC: 9629502. DOI: 10.1093/femsre/fuac031.
Sanchez-Villamil J, Tapia D, Torres A mSphere. 2022; 7(1):e0093421.
PMID: 35044806 PMC: 8769200. DOI: 10.1128/msphere.00934-21.